FTC Targets AbbVie, Teva In 1st New Pay-For-Delay Suit
The Federal Trade Commission accused AbbVie Inc. on Monday of keeping Teva Pharmaceuticals USA Inc.'s generic AndroGel off the market through a side licensing deal, and experts say the watchdog's first...To view the full article, register now.
Already a subscriber? Click here to view full article